Company Description
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.
The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders.
The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 2003 |
| IPO Date | Jun 1, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,800 |
| CEO | Bruce Cozadd |
Contact Details
Address: Waterloo Exchange, Fifth Floor Dublin, D04 E5W7 Ireland | |
| Phone | 353 1 634 7800 |
| Website | jazzpharma.com |
Stock Details
| Ticker Symbol | JAZZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001232524 |
| CUSIP Number | G50871105 |
| ISIN Number | IE00B4Q5ZN47 |
| Employer ID | 98-1032470 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bruce C. Cozadd | Co-Founder, Chairman and Chief Executive Officer |
| Renee D. Gala | President and Chief Operating Officer |
| Patricia Carr | Senior Vice President and Chief Accounting Officer |
| Neena M. Patil J.D. | Executive Vice President and Chief Legal Officer |
| Dr. Robert Iannone M.D. | Executive Vice President, Chief Medical Officer and Global Head of Research and Development |
| Philip L. Johnson | Executive Vice President and Chief Financial Officer |
| Andrea N. Flynn Ph.D. | Vice President and Head of Investor Relations |
| Heidi Manna | Executive Vice President and Chief People Officer |
| Dr. Jed Black M.D. | Senior Vice President of Sleep and CNS Medicine |
| Samantha Pearce | Executive Vice President and Chief Commercial OfficerChief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 144 | Filing |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 1, 2024 | 144 | Filing |
| Oct 21, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 16, 2024 | 8-K | Current Report |
| Sep 6, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 144 | Filing |